|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Butein-mediated antitumor activities were substantially impaired in Aurora B knockdown cells, suggesting Aurora B was an important target of butein in HCC.
|
30263005 |
2018 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Liver carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
We investigated the role of Aurora B expression in both HCC and matched adjacent non-tumor tissue.
|
23893130 |
2014 |
|
Liver carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Although the expression level of AURKB-a validated target for miR-24-was reduced upon miR-24 overexpression in hepatocarcinoma HEP-G2 cells, overexpression of miR-24 cannot alter AURKB expression levels in MHH-CALL-3 TCF3-rearranged leukemic cells.
|
24153013 |
2014 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Using two models of apparent diploid vs. tetraploid cell lines (one based on the hepatocellular carcinoma cell line Hep3B and another on untransformed mouse fibroblasts), we found that tetraploid cells were more sensitive to Aurora B inhibition than their diploid counterparts.
|
22722494 |
2012 |
|
Liver carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Aurora B was overexpressed in 98 (61%) of 160 HCCs and in all 7 HCC cell lines examined.
|
20799978 |
2010 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Our preclinical studies indicate that Aurora kinase B is a promising molecular target "Achilles' heel" for the treatment of aggressive HCC.
|
19941009 |
2010 |
|
Liver carcinoma
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
The results thus suggest that AURKB-Sv2 variant form is more significantly associated with the advanced stages of HCC than others and is a marker of poor prognosis.
|
19134008 |
2009 |
|
Liver carcinoma
|
0.380 |
AlteredExpression
|
disease |
LHGDN |
The results thus suggest that AURKB-Sv2 variant form is more significantly associated with the advanced stages of HCC than others and is a marker of poor prognosis.
|
19134008 |
2009 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Multivariable analysis identified Aurora kinase B as the only independent predictor of aggressive recurrence of HCC (P = 0.031).
|
18311747 |
2008 |
|
Malignant neoplasm of stomach
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Association with increased GC risk was demonstrated for AURKB rs2241909 (GG + AG vs. AA: OR, 1.61; 95% CI, 1.01-2.56; p = 0.041) and rs2289590 (AC vs. AA: OR, 2.41; 95% CI, 1.47-3.98; p = 0.001; CC vs. AA: OR, 6.77; 95% CI, 2.24-20.47; p = 0.001; AA+AC vs. CC: OR, 4.23; 95% CI, 1.44-12.40; p = 0.009).
|
31521144 |
2019 |
|
Malignant neoplasm of stomach
|
0.350 |
Biomarker
|
disease |
BEFREE |
Therefore, these findings provide new evidence that barasertib regulates GC cell glucose metabolism by inducing the RPS7/C-Myc signal pathway, and have important implications for the development of therapeutic approaches using AURKB as a target protein to prevent tumor recurrence.
|
30540594 |
2019 |
|
Malignant neoplasm of stomach
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggested that AURKA (rs911160) and AURKB (rs2289590) polymorphisms could affect GC risk.
|
28843004 |
2017 |
|
Malignant neoplasm of stomach
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
We genotyped four SNPs in AURKA (rs2273535 and rs1047972), AURKB (rs2241909), and AURKC (rs758099) in a total of 128 GC patients and 372 healthy controls using TaqMan allelic discrimination assays to evaluate their effects on GC risk.
|
27270838 |
2016 |
|
Malignant neoplasm of stomach
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that an overexpression of Aurora-B, but not of Aurora-A, might contribute to DNA aneuploidy in gastric cancers by promoting chromosomal instability.
|
23572383 |
2014 |
|
Malignant neoplasm of stomach
|
0.350 |
Biomarker
|
disease |
CTD_human |
Survivin and Aurora-B are strongly expressed in human AGS gastric cancer cells and co-localize during mitosis.
|
15993841 |
2005 |
|
IGA Glomerulonephritis
|
0.300 |
Biomarker
|
disease |
CTD_human |
The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy.
|
25133636 |
2014 |
|
Stomach Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B.
|
15993841 |
2005 |
|
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B.
|
15993841 |
2005 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Aurora kinase B (AURKB) and Ubiquitin conjugating enzyme E2C (UBE2C) are involved in tumorigenesis of gliomas and other malignancies as well, but their clinicopathologic significance in gliomas is unknown and the prognostic value of combined expression of AURKB and UBE2C has not been explored.
|
31353228 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromosomal passenger complex (CPC) has been demonstrated to be a potential target of cancer therapy by inhibiting Aurora B or survivin in different types of cancer including neuroblastoma.
|
31416840 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Neither baseline tumor expression of AURKA (ROC = 0.57, P = 0.46) nor AURKB (ROC = 0.56, P = 0.87) predicted for ypT2-4 status.
|
31597600 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We did a CRISPR/Cas9-based screen that showed that <i>RB1</i><sup>-/-</sup> SCLC are hyperdependent on <i>AURKB</i>, likely because both genes control mitotic fidelity, and confirmed that Aurora B kinase inhibitors are efficacious against <i>RB1</i><sup>-/-</sup> SCLC tumors in mice at nontoxic doses.<i>See related commentary by Dick and Li, p. 169</i>.<i>This article is highlighted in the In This Issue feature, p. 151</i>.
|
30373918 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Potential Molecular Mechanisms of AURKB in the Oncogenesis and Progression of Osteosarcoma Cells: A Label-Free Quantitative Proteomics Analysis.
|
31122179 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Afterwards, the potential biological functions of AURKB in oncogenesis and chemoresistance were investigated by lentivirus-dependent silencing of AURKB combined with qRT-PCR, western blot and in vivo intra-cranial xenograft mice models.
|
31563286 |
2019 |